(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.78% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Haleon's revenue in 2025 is $14,588,311,688.On average, 4 Wall Street analysts forecast HLN's revenue for 2025 to be $134,942,899,789,490, with the lowest HLN revenue forecast at $131,946,478,371,767, and the highest HLN revenue forecast at $136,249,984,363,153. On average, 3 Wall Street analysts forecast HLN's revenue for 2026 to be $141,909,926,811,119, with the lowest HLN revenue forecast at $141,241,037,569,347, and the highest HLN revenue forecast at $142,620,764,699,184.
In 2027, HLN is forecast to generate $147,961,268,841,483 in revenue, with the lowest revenue forecast at $146,898,472,908,960 and the highest revenue forecast at $149,299,574,181,129.